Biogen Pharmachem Industries Ltd (BIOGEN) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Biogen Pharmachem Industries Ltd on NSE and BSE, with an AI summary of each filing.
PFA
Others (Uncategorized) · 03 Nov 2026, 8:56 pm
Biogen Pharmachem Reports Nil Unutilised Issue Proceeds as of Sep'26 Biogen Pharmachem Industries Limited submitted its disclosure under Regulation 32(1) of SEBI LODR Regulations to BSE on 3rd Nov'26. The company confirmed that it has no unutilised funds remaining as of 30th Sep'26 or as of the filing date from any previous public issues, rights issues, preferential issues, or qualified institutional placements (QIPs). Consequently, no statement of deviation or variation was required under Annexure-A.
PFA
Financial Result · 03 Nov 2026, 8:51 pm
Biogen Pharmachem Reports Q2 FY27 Results with Net Profit of Rs 25.73 Lakhs Biogen Pharmachem Industries reported zero operational revenue for the quarter ended 30th Sep'26, relying entirely on other income of Rs 28.33 lakhs, down 36.1% QoQ but recovering from negative Rs 10.49 lakhs in Q2 FY26. Total expenses fell sharply to Rs 2.61 lakhs compared to Rs 22.20 lakhs in Q1 FY27 and Rs 38.67 lakhs YoY. Net profit stood at Rs 25.73 lakhs versus a net loss of Rs 49.15 lakhs in Q2 FY26. Basic and diluted EPS for the quarter was Rs 0.00.
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 03 Nov 2026, 8:42 pm
Biogen Pharmachem Reports Q2 Results with ₹25.73 Lakh Profit Biogen Pharmachem Industries posted a net profit of ₹25.73 lakh for the quarter ended 30th Sep'26, turning around from a net loss of ₹49.15 lakh in the year-ago period and up 16.2% QoQ from ₹22.14 lakh. Core operational revenue remained nil, with total income entirely driven by other income of ₹28.33 lakh versus negative ₹10.49 lakh YoY. Total expenses fell sharply to ₹2.61 lakh from ₹38.67 lakh YoY. For H1 ended 30th Sep'26, net profit reached ₹47.87 lakh compared to ₹85.33 lakh YoY.
Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Pursuant to ....
Intimation · 03 Nov 2026, 5:30 am
Biogen Pharmachem Industries Schedules Board Meeting for Q2 FY27 Financial Results Biogen Pharmachem Industries Limited has scheduled a meeting of its Board of Directors on 3rd Nov'26. The board will convene primarily to consider, approve, and take on record the company's unaudited financial results for the second quarter and half-year ended 30th Sep'26, alongside other general business matters.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd
Acquisition/ Disposal of Shares · 23 Oct 2026, 3:38 pm
Rama Shiva Lease Finance Fully Exits Stake in Biogen Pharmachems Rama Shiva Lease Finance Private Limited offloaded its entire holding of 4,25,83,333 equity shares (representing a 4.04% stake) in Biogen Pharmachems Industries Limited via open market sale on 16th Oct'26. Following this disposal, Rama Shiva Lease Finance holds zero shares and voting rights in the company, bringing its post-transaction stake down from 4.04% to 0.00% of the total equity share capital of 1,05,30,36,833 shares (face value Rs. 1 each).
PFA
Annual General Meeting · 30 Sept 2026, 12:06 am
Biogen Pharmachem Industries AGM Voting Results Biogen Pharmachem Industries announced the voting results for its 31st Annual General Meeting held on 29th Sep'26. Shareholders approved all three ordinary resolutions with overwhelming majorities: adoption of audited financial statements for the fiscal year ended 31st Mar'26 (99.98% in favor), the re-appointment of retiring director Kelash Bunkar (99.64% in favor), and the appointment of M/s. Goenka Mehta & Associates, Chartered Accountants, as statutory auditors along with fixing their remuneration (99.93% in favor). Total voter turnout represented 5.254% of outstanding shares.
PFA
Annual General Meeting · 29 Sept 2026, 11:35 pm
Biogen Pharmachem Shareholders Approve FY26 Financials and Auditor Appointment at AGM Biogen Pharmachem Industries Limited held its 31st Annual General Meeting on 29th Sep'26, where shareholders approved all key ordinary resolutions. Key outcomes include the formal adoption of audited financial statements for the fiscal year ended 31st Mar'26, the re-appointment of retiring director Mr. Kelash Bunkar, and the appointment of M/s. Goenka Mehta & Associates, Chartered Accountants, as the company's new statutory auditors alongside the fixation of their remuneration. Complete voting results under Regulation 44(3) are to be submitted separately.
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial ....
Others (Uncategorized) · 04 Sept 2026, 7:05 pm
PFA
Annual General Meeting · 04 Sept 2026, 6:56 pm
Biogen Pharmachem Industries Schedules 31st AGM and Auditor Re-appointment Biogen Pharmachem Industries Limited has scheduled its 31st AGM for 29th Sep'26 via video conferencing. Key agenda items include adopting FY26 audited financial statements, the re-appointment of Director Kelash Bunkar upon rotational retirement, and reappointing M/s Goenka Mehta & Associates as statutory auditors through the 2031 AGM. The register of members and share transfer books will remain closed from 22nd Sep'26 to 29th Sep'26, with the cut-off date for remote e-voting set for 22nd Sep'26 (e-voting window runs from 26th Sep'26 to 28th Sep'26).
PFA
Others (Uncategorized) · 05 Aug 2026, 9:36 pm
Biogen Pharmachem Confirms No Unutilized Funds from Past Capital Raises Biogen Pharmachem Industries disclosed on 05 Aug'26 that it has no unutilized funds remaining as of 30 Jun'26. This statement pertains to proceeds from any past public issues, rights issues, preferential issues, or qualified institutional placements (QIPs). The company confirmed full deployment of capital raised, and therefore, no statement of deviation or variation in the use of proceeds was provided. This update was filed with the BSE under Regulation 32(1) of SEBI's listing obligations.
PFA
Financial Result · 05 Aug 2026, 9:24 pm
Biogen Pharmachem Swings to Profit in Q1FY27 on Lower Expenses Biogen Pharmachem reported a net profit of ₹22.14 lacs for Q1 ended 30-Jun-26, a significant turnaround from a loss of ₹35.88 lacs in Q4FY26. This was driven by a sharp 76% QoQ decline in total expenses to ₹22.20 lacs, despite revenue from operations falling 23% QoQ to ₹44.34 lacs. On a YoY basis, the company's net profit dropped 84% from ₹134.48 lacs in Q1FY26, while revenue also saw a steep 71% YoY decline. Basic and diluted EPS for the quarter stood at ₹0.00.
Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Outcome · 05 Aug 2026, 9:13 pm
Biogen Pharmachem Reports Q1 Results, Swings to Profit Sequentially Biogen Pharmachem reported a net profit of Rs 22.14 lacs for the quarter ended 30-Jun-26, a significant turnaround from a loss of Rs 35.88 lacs in the prior quarter. Revenue from operations declined 23.3% QoQ to Rs 44.34 lacs. However, on a YoY basis, revenue fell 71.3% from Rs 154.28 lacs, while net profit decreased 83.5% from Rs 134.48 lacs. The profit recovery QoQ was driven by a sharp 76.3% reduction in total expenses to Rs 22.20 lacs. EPS for the quarter stood at Rs 0.00.
Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 05 Aug 2026, 5:30 am
Biogen Pharmachem Board Meeting Set for Q1 FY27 Results Biogen Pharmachem Industries (BSE: 531752) has scheduled a Board of Directors meeting for 5th Aug'26. The primary agenda is to consider and approve the un-audited financial results for the first quarter ending 30th Jun'26. The board may also discuss other matters with the chair's permission. This meeting is a key event for investors tracking the company's Q1 FY27 performance.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd
Acquisition/ Disposal of Shares · 20 May 2026, 3:34 pm
Rama Shiva Lease Finance Reduces Stake in Biogen Pharmachem Rama Shiva Lease Finance Pvt Ltd has sold 4,75,00,000 shares, representing 5.26% of Biogen Pharmachem Industries Ltd (BIOGEN), via an open market transaction on 18 May'26. Following the sale, Rama Shiva's holding has decreased from 8,40,00,000 shares (9.31%) to 3,65,00,000 shares (4.04%). Biogen Pharmachem's total voting capital remains at Rs. 90,26,03,000, comprising 90,26,03,000 equity shares of Rs. 2 each. Rama Shiva is not part of the promoter group.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd
Acquisition/ Disposal of Shares · 20 May 2026, 3:31 pm
Biogen Pharmachem: Non-Promoter Sells 5.26% Stake via Open Market Rama Shiva Lease Finance Private Limited, a non-promoter entity, sold 47.5M shares of Biogen Pharmachem Industries, constituting a 5.26% stake, through an open market transaction on 18 May'26. Following the sale, its shareholding in the company decreased from 9.31% to 4.04%. The total voting capital of Biogen Pharmachem remains unchanged at 902.6M shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Parichay Infrastructure Ltd
Acquisition/ Disposal of Shares · 20 May 2026, 3:23 pm
Parichay Infra Sells 4.42% Stake in Biogen Pharmachem via Open Market Parichay Infrastructure sold 3,99,32,000 shares, a 4.42% stake, in Biogen Pharmachem Industries (BSE: 531752) via an open market transaction on 18 May'26. This sale reduced Parichay's holding in Biogen from 9.08% (8,20,00,000 shares) to 4.66% (4,20,68,000 shares). The disclosure was made under SEBI's substantial acquisition and takeover regulations. Biogen's total voting capital remains at Rs. 90.26 crore, comprising 90,26,03,000 equity shares with a face value of Rs. 2 each.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Interface Financial Services Ltd
Acquisition/ Disposal of Shares · 19 May 2026, 10:47 pm
Interface Financial Sells 4.47% Stake in Biogen Pharmachem Interface Financial Services Ltd disclosed the sale of 4,03,03,000 shares, representing a 4.47% stake in Biogen Pharmachem Industries (BSE: 531752), through an open market transaction on 18 May'26. Following the sale, Interface Financial's holding in Biogen Pharmachem decreased from 9.31% (8,40,00,000 shares) to 4.84% (4,36,97,000 shares). The acquirer was not part of the promoter group. The target company's total equity capital remains at Rs. 90.26 crore, comprising 90,26,03,000 shares of Rs. 2 each.
PFA
Others (Uncategorized) · 18 May 2026, 10:54 pm
Biogen Pharmachem Allots 15.04 Crore Bonus Shares, Increasing Capital Biogen Pharmachem's Board of Directors, on 18 May'26, allotted 15,04,33,833 bonus equity shares. This action increased the company's paid-up and issued capital from Rs. 90,26,03,000 (90.26 crore shares) to Rs. 1,05,30,36,833 (105.30 crore shares). The newly issued bonus shares, with a face value of Rs. 1/- each, were credited to eligible shareholders' accounts on the same day.
PFA
Others (Uncategorized) · 14 May 2026, 10:25 pm
Biogen Pharmachem Confirms No Unutilized Funds from Past Issues Biogen Pharmachem Industries Limited informed the exchange on 14 May'26 that it has no unutilized funds remaining as of 31 Mar'26. This pertains to any proceeds from past public issues, rights issues, preferential issues, or Qualified Institutional Placements (QIPs). The company filed a "nil" statement regarding deviation or variation in the use of proceeds under SEBI's Regulation 32(1), indicating full deployment of any capital raised previously. Consequently, no further details were provided in an annexure.
PFA
Financial Result · 14 May 2026, 10:16 pm
Biogen Pharmachem Reports FY26 Results, Posts Net Loss in Q4 Biogen Pharmachem reported a net loss of Rs. 35.88 lacs for Q4 FY26, a sharp reversal from a profit of Rs. 46.23 lacs in Q3 FY26 and a loss of Rs. 29.27 lacs in Q4 FY25. For the full year ended 31 Mar'26, the company posted a net profit of Rs. 85.95 lacs, a significant turnaround from a loss of Rs. 29.27 lacs in FY25. Total annual income grew to Rs. 255.80 lacs from Rs. 83.84 lacs YoY. The auditor issued an unmodified opinion on the financial statements.
This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Thursday 14th May 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Outcome · 14 May 2026, 10:12 pm
Biogen Pharmachem Reports FY26 Results, Showing Net Loss in Q4 Biogen Pharmachem reported a net loss of Rs 35.88 lacs for Q4 FY26, a significant decline from a net profit of Rs 46.23 lacs in Q3 FY26 and Rs 117.78 lacs in Q4 FY25. For the full year ended 31 Mar’26, net profit was Rs 85.95 lacs, a sharp increase from a net loss of Rs 29.27 lacs in FY25. Revenue from operations for Q4 FY26 stood at Rs 57.82 lacs. The Board approved the audited results on 14 May’26, with an unmodified opinion from the auditor.
Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Pursuant to Regulation ....
Intimation · 14 May 2026, 5:30 am
Biogen Pharmachem Board Meeting Set for May 14 to Approve FY26 Results Biogen Pharmachem Industries (BSE: 531752) has scheduled a Board of Directors meeting on 14th May'26. The primary agenda is to consider and approve the audited standalone financial results for the quarter and fiscal year ending 31st Mar'26. The Board will also take on record the accompanying auditor's report. Any other relevant matters may also be discussed with the Board's permission. This announcement is a key corporate action for investors awaiting the company's full-year performance data.
PFA
Others (Uncategorized) · 28 Apr 2026, 1:00 am
Biogen Pharmachem Shareholders Approve Bonus Issue & Increase in Authorised Capital Biogen Pharmachem Industries announced that on 27 Apr'26, members approved special resolutions for a bonus share issue and a corresponding increase in the company's authorised share capital. The approvals were obtained via a Postal Ballot Notice dated 23 Mar'26. This corporate action necessitates an amendment to the Capital Clause of the company's Memorandum of Association.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 22 Apr 2026, 11:29 pm
Biogen Pharmachem Confirms Non-Applicability of Large Corporate Framework Biogen Pharmachem Industries Ltd has informed the BSE on 22 Apr'26 that it does not qualify as a Large Corporate under SEBI's framework for fundraising via debt securities. Consequently, the company is not required to make the mandated Initial and Annual Disclosures for the financial year ended 31 Mar'26. The filing notes the company has zero outstanding borrowings and no credit rating. This exempts Biogen from the requirement to raise a portion of its incremental borrowings through debt securities.
PFA
Bonus Issue · 01 Apr 2026, 5:11 pm
Biogen Pharmachem Sets Record Date for 1:6 Bonus Share Issue Biogen Pharmachem Industries (BSE: 531752) has announced a bonus issue of equity shares in a 1:6 ratio, providing one new share for every six existing shares held. The face value of each share is Rs. 1/-. The company has fixed Fri, 15th May'26 as the record date to determine shareholder eligibility for the bonus issue. The action is subject to shareholder approval, which is being sought via a postal ballot and e-voting process.